HAOHAI BIOTEC (06826) reported a net profit attributable to shareholders of approximately RMB 163 million for the first three quarters, a year-on-year decrease of 46.53%.
HAOHAI BIOTEC (06826) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB 1.71 billion, a year-on-year decrease of 9.93%; net profit attributable to shareholders of the listed company of approximately RMB 163 million, a year-on-year decrease of 46.53%; and basic earnings per share of RMB 0.71.
HAOHAI BIOTEC (06826) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB 1.71 billion, a year-on-year decrease of 9.93%; net profit attributable to shareholders of the listed company of approximately RMB 163 million, a year-on-year decrease of 46.53%; and basic earnings per share of RMB 0.71.
Related Articles
China Shenhua Energy (01088) plans to spend approximately RMB 618 million to acquire a 50% equity stake in a coal-to-gas company.
POLY XVERSE IT (00209) completes placement of 29.71 million shares, raising net proceeds of approximately HK$10.35 million
JUNSHI BIO (01877): First patient dosed in Phase III clinical trial of JS203 combined with chemotherapy for the treatment of diffuse large B-cell lymphoma
China Shenhua Energy (01088) plans to spend approximately RMB 618 million to acquire a 50% equity stake in a coal-to-gas company.
POLY XVERSE IT (00209) completes placement of 29.71 million shares, raising net proceeds of approximately HK$10.35 million
JUNSHI BIO (01877): First patient dosed in Phase III clinical trial of JS203 combined with chemotherapy for the treatment of diffuse large B-cell lymphoma
